Evidence map›Paper›PMID 27900638›Full record

Trial reportInternational journal of hematology2017

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki and 15 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 18 institutions in 2 countries.

Michinori OguraDepartment of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan. mi-ogura@naa.att.ne.jp.
Kenichi IshizawaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Naokuni UikeDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University Hospital, Isehara, Japan.
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Yasuhito TeruiDepartment of Hematology Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Kunihiro TsukasakiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tohru IzumiDivision of Hematology, Tochigi Cancer Center, Utsunomiya, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Tomohiro KinoshitaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Masafumi TaniwakiDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nobuhiko UoshimaDepartment of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
Junji SuzumiyaDepartment of Oncology/Hematology, School of Medicine, Shimane University, Izumo, Japan.
Mitsutoshi KurosawaDepartment of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Toshiki UchidaDepartment of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ilseung ChoiDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Ken OhmachiDepartment of Hematology and Oncology, Tokai University Hospital, Isehara, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Japanese Bendamustine Lymphoma Study Group
Japanese Red Cross Nagoya Daini Hospital · JPNational Hospital Organization Kyushu Cancer Center · JPTohoku University · JPTokai University Hospital · JPTokyo National Hospital · JPToranomon Hospital · JPAichi Cancer Center · JPJapanese Red Cross Medical Center · JPKyoto Prefectural University of Medicine · JPMatsushita Memorial Hospital · JPNagasaki University Hospital · JPNagoya Medical Center · JPNational Cancer Center Hospital East · JPNTT Medical Center · JPSapporo National Hospital · JPShimane University · JPThe Cancer Institute Hospital · JPTochigi Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A Phase II, multicenter clinical trial of bendamustine plus rituximab (BR) regimen was conducted in previously untreated patients with high-tumor-burden indolent B-cell non-Hodgkin lymphoma (B-NHL) and previously untreated elderly patients with mantle cell lymphoma (MCL) in Japan. Bendamustine 90 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideDisease-Free SurvivalFemaleHumansJapanLeukopeniaLymphoma, B-CellLymphoma, Mantle-CellMaleMiddle AgedNeutropeniaRemission InductionRituximabBendamustine HydrochlorideRituximabBendamustineFirst-line therapyIndolent B-cell non-Hodgkin lymphomaMantle cell lymphomaRituximab

Identifiers

PMID27900638
OpenAlexW2559707087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.